Detalles de la búsqueda
1.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441846
2.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390143
3.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695144
4.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36458426
5.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608562
6.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Am J Hematol
; 98(4): 658-665, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36683287
7.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37515433
8.
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
Am J Hematol
; 98(9): 1383-1393, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37334870
9.
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Acta Haematol
; 146(6): 522-529, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699357
10.
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
Cancer
; 128(14): 2736-2745, 2022 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35452134
11.
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
Am J Hematol
; 97(11): 1427-1434, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36053747
12.
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Am J Hematol
; 97(11): 1413-1418, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054032
13.
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.
Am J Hematol
; 97(11): E408-E411, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054774
14.
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
Am J Hematol
; 97(1): 68-78, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716921
15.
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Am J Hematol
; 97(3): 329-337, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981570
16.
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
Am J Hematol
; 97(7): 885-894, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35413152
17.
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Am J Hematol
; 97(12): 1599-1606, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117258
18.
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Am J Hematol
; 97(11): 1443-1452, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054614
19.
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Clin Infect Dis
; 72(10): 1755-1763, 2021 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236406
20.
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Cancer
; 127(19): 3541-3551, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34182597